Miniatura

Fitxers

691710.pdf (188.61 KB)

Tipus de document

Article

Data de publicació

2019-08-14

Llicència de publicació

cc-by (c) Pérez Areales, Francisco Javier et al., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/165965

Synthesis, in vitro profiling, and in vivo efficacy studies of a new family of multitarget anti-Alzheimer compounds

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/proceedings2019022071

Resum

Simultaneous modulation of several targets or pathological events with a key pathogenic role is a promising strategy to tackle thus far difficult-to-cure or incurable multifactorial diseases, such as Alzheimer's disease (AD). In this scenario, multitarget compounds, i.e., single molecules that hit several targets, are superior to other multitarget strategies that are based on the use of more than one drug (drug cocktails, fixed-dose combinations), in terms of simpler drug development and better patient compliance, efficiency, and safety. In the frame of our research line devoted to the development of novel anti-AD drug candidates, we have recently prepared a new class of multitarget compounds, which were designed by combining pharmacophoric moieties of a known antioxidant agent (7-methoxy-2,2- dimethylchroman-6-ol (CR-6)) and an acetylcholinesterase (AChE) inhibitor (6-chlorotacrine), to primarily address two important pathological events of AD, namely oxidative stress and cholinergic deficit. Here, we present the synthesis of three short series of CR-6-chlorotacrine hybrids, featuring different linker functionalities (amide, inverse amide, or amine) and lengths, and their in vitro biological activities against AChE, butyrylcholinesterase, BACE-1, and β-amyloid and tau protein aggregation, their antioxidant activity, and BBB permeability. We will also show the results of the in vivo efficacy studies of two selected compounds in double transgenic APP/PS1 mice, a wellestablished mouse model of AD (behavioral studies, effects on amyloid pathology and oxidative stress).

Matèries

Malaltia d'Alzheimer, Malalties neurodegeneratives, Química farmacèutica

Matèries (anglès)

Alzheimer's disease, Neurodegenerative Diseases, Pharmaceutical chemistry

Citació

Col·leccions

Articles publicats en revistes (Nutrició, Ciències de l'Alimentació i Gastronomia)
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Institut de Biomedicina (IBUB))

Citació

PÉREZ AREALES, Francisco javier, GARRIDO, María, ASO PÉREZ, Ester, BARTOLINI, Manuela, DE SIMONE, Angela, ESPARGARÓ COLOMÉ, Alba, GINEX, Tiziana, SABATÉ LAGUNAS, Raimon, PÉREZ, Belén, ANDRISANO, Vincenza, LUQUE GARRIGA, F. xavier, FERRER, Isidro (ferrer abizanda), CIRUELA ALFÉREZ, Francisco, MESSEGUER I PEYPOCH, Àngel, MUÑOZ-TORRERO LÓPEZ-IBARRA, Diego. Synthesis, in vitro profiling, and in vivo efficacy studies of a new family of multitarget anti-Alzheimer compounds. _MDPI Proceedings_. 2019. Vol. 22, núm. 71. [consulta: 27 de gener de 2026]. ISSN: 2504-3900. [Disponible a: https://hdl.handle.net/2445/165965]

Exportar metadades

JSON - METS

Compartir registre